key: cord-0794697-w650vind
authors: Coste, Alix T.; Jaton, Katia; Papadimitriou-Olivgeris, Matthaios; Greub, Gilbert; Croxatto, Antony
title: Comparison of SARS-CoV-2 serological tests with different antigen targets
date: 2020-11-17
journal: J Clin Virol
DOI: 10.1016/j.jcv.2020.104690
sha: 2d9d38fcbe67f6b03b927a71c88b83c42e838e74
doc_id: 794697
cord_uid: w650vind

Background These last months, dozens of SARS-CoV-2 serological tests have become available with varying performances. A major effort was completed to compare 17 serological tests available in April 2020 in Switzerland. Methods In a preliminary phase, we compared 17 IgG, IgM, IgA and pan Ig serological tests including ELISA, LFA, CLIA and ECLIA on a panel of 182 sera, comprising 113 sera from hospitalized patients with a positive RT-PCR, and 69 sampled before 1 st November 2019, expected to give a positive and negative results, respectively. In a second phase, the five best performing and most available tests were further evaluated on a total of 582 sera (178 and 404 expected positive and negative, respectively), allowing the assessment of 20 possible cross-reactions with other virus. Results In the preliminary phase, among eight IgG/pan-Ig ELISA or CLIA/ECLIA tests, five had a sensitivity and specificity above 90% and 98% respectively, and on six IgM/IgA tests, only one was acceptable. Only one LFA test on three showed good performances for both IgG and IgM. For all the tests IgM and IgG aroused concomitantly. In the second phase, no tests showed particular cross-reaction. We observed an important heterogeneity in the development of the antibody response. Conclusions The majority of the evaluated tests exhibited high performances of IgG/pan-Ig sensitivity and specificity to detect the serological response of moderately to critically ill hospitalized patients. The IgM and IgA tests showed mostly insufficient performance with no added value for the early diagnostic on the cohort tested in this study.

(https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid- 19) .

The mortality rate of the SARS-CoV-2 (about 2%) is lower than SARS-CoV-1 and MERS-CoV (Middle East Respiratory Syndrome Coronavirus) (10 and 30%, respectively) but its reproduction rate R0 (2 to 2.5) is higher, than the SARS-CoV-1 (1.7 to 1.9) and the MERS-CoV (<1), probably explaining its rapid spreading worldwide [1] [2] [3] .

In a first phase of the pandemic, nucleic acid amplification tests (NAAT) enabled rapid detection of infected patients, their sorting and their possible isolation. In a second phase, serology testing appeared particularly important as it permits to diagnose patients after the acute phase of the infection or with atypical clinical presentation with no nasopharyngeal shedding of the virus [4, 5] . Indeed, in contrast to NAAT, which must be carried out when and where the virus is excreted, the serological assays might be performed anytime ideally more than two weeks after symptoms onset [4] . Serology also appeared to be the tests of choice to perform large-scale population prevalence studies.

Various SARS-CoV-2 serological tests using different targeted antigenic proteins have been arriving on the market the last months (https://www.finddx.org/covid-19/pipeline). Some of them use whole virus lysate, recombinant full S (spike) or N (nucleocapsid) proteins, peptides of the N or specific domains S1, S2 or RBD (receptor-binding domains) of the S protein.

Different studies demonstrated that the S and N proteins were the most immunogenic [4, [6] [7] [8] . The N protein is relatively small with no glycosylated sites and presents a higher level of conservation than the S protein among coronavirus infecting human, allowing possible false positive results through cross-reaction [4, 9, 10] . In contrast the S protein is a large J o u r n a l P r e -p r o o f more complex conformation, leading to production of more specific antibodies often recognizing conformational or glycosylated epitopes [9] [10] [11] . Thus the use of recombinant S protein lacking glycosylation or conformation in immunoassays may lead to false negative results.

In this study we evaluated several SARS-CoV-2 serological tests available in April 2020 in Switzerland including ELISA (Enzyme-Linked ImmunoSorbent Assays), LFA (Lateral Flow ImmunoAssays), CLIA (ChemiLuminescent ImmunoAssays) or ECLIA (Electro-ChemiLuminescent ImmunoAssays). This evaluation aimed to identify high quality tests for symptomatic patients. (Table S1 ). Then, the evaluation was completed for the selected tests on 400 sera (65 positive and 335 negative), leading to a full evaluation performed on 582 sera (178 positive and 404 negative) (Table S1 ). Negative-expected sera were selected among sera sampled before the 1 st November 2019 and indicated as "Anterior" for anterior to SARS-CoV-2 pandemic (Table S1) . Possible cross-reactivity was assesses through testing of sera known to be positive for a given microorganism, indicated as "Anterior (microorganism)". The 178 expected positive sera were sampled during the first 2 months post-symptoms from patients documented with a positive SARS-CoV-2 RT-PCR and with a dates of symptoms in their electronic records.

Each test (Table S2) 

A preliminary evaluation of 17 serological kits (Table S2) Interestingly, we observed a simultaneous IgM and IgG response overtime for the tests with an IgM specificity above 90% (Dynamiker LFA, NADAL LFA and Snibe CLIA) (Figure 1 ). The four IgG tests demonstrated good sensitivity (≥96%) and specificity (≥98%) performances at more than 15 days post-symptoms, except the Diasorin ISON® SARS-CoV-2 IgG CLIA kit that showed a sensitivity of 92% (95% CI:83-96) but with a specificity of 100% ( Figure 4 , Table S6 ). The IgM tests exhibited a sensitivity of 91% (95% CI:95-92), and a specificity of 98% (95% CI:96-99) for the CLIA Snibe IgM test with, and a sensitivity of 97 % (95% CI:91-100) and a specificity of 96% (95% CI:94-98) for the LFA Dynamiker IgM test ( Figure 4 , Table S6 ).

We analyzed the development of the IgG semi-quantitative response overtime postsymptoms with the ED ELISA targeting the anti-N response, the Diasorin CLIA targeting the anti-S1-S2 domains of the S protein, and the Snibe CLIA targeting both N and S proteins 

To our knowledge, this study is the first one comparing so many different serologic tests for SARS-CoV-2 diagnostic using different technologies, LFA, ELISA, CLIA and ECLIA, on sera from RT-PCR positive patients collected over one to two months post-symptoms, and assessing 20 possible cross reaction with other viral infections.

This large evaluation of 17 SARS-CoV-2 serological tests highlights in the preliminary phase that among eight IgG/pan-Ig ELISA or CLIA/ECLIA tests, five were recommended with a combined sensitivity above 90% and specificity above 98% (Epitope Diagnostic, Vircell and Creative Diagnostic IgG ELISA tests, Snibe IgG CLIA and Roche pan-Ig ECLIA tests), and that on six IgM/IgA ELISA or CLIA/ECLIA tests, only one (Snibe IgM CLIA) was acceptable with a combined sensitivity above 80% and specificity of 99%.

Concerning LFA, only one test showed good performances for both IgG and IgM, showing that a thorough evaluation is absolutely required before use especially, outside referenced diagnostic laboratories.

For all different tests, we observed that IgM and IgG aroused concomitantly, as already described for SARS-CoV-1 and 2 infection [5, 12, 13] . However, other studies demonstrated a higher sensitivity of IgM than IgG detection during the first 14 days post-symptoms [14] . It is therefore difficult to determine if the difference observed is due to a difference in IgM and IgG kinetic response between the different cohorts or if it is due to the performances of the different kits used in the different studies. In any case, this suggests that the use of IgM for the sero-diagnostic of SARS-CoV-2 acute/subacute infection might be difficult either due to physiological or technical limitations. Thus, SARS-CoV-2 RT-PCR remains the test of choice for early diagnostic a few days after symptoms onset [15] . In our hand, the anti-N and anti-S antibodies were both detectable during the acute phase of the CoviD-19 disease for hospitalized patients. Previous studies on other coronavirus [4] , or on SARS-CoV-2 [16] suggest that the anti-N antibody response may appeared earlier or simultaneously than the anti-S response and may also waned more rapidly after few months [17] . In contrast, other studies focusing also on severe patient in acute phase of the disease demonstrated an anti-RBD response earlier than the anti-N response [13, 18] . As we did not evaluate serological tests targeting anti-RBD only, we cannot exclude that antibodies This study has identified several SARS-CoV-2 tests exhibiting very good sensitivity and specificity from sera collected from hospitalized patients up to 30-60 days post-symptoms.

Parallel works performed in our laboratory on seroprevalence cohort [19] or on routine patients [20] suggest that the serology of SARS-CoV-2, completed with good quality tests, may be used for seroprevalence studies [19] and, in several clinical and epidemiological assets to confirm or exclude a CoviD-19 disease including i) suggestive clinical symptoms with two consecutive negative RT-PCR, or ii) suggestive clinical symptoms with discordant RT-PCRs, iii) infectious control settings for hospitalized patients presenting more than 20 days old suggestive clinical symptoms, iv) CoviD-19 atypical clinical presentations (Guillain-Barré syndrome, meningo-encephalitis, cutaneous vasculitis, Kawasaki disease, diarrhea,…) with negative RT-PCR and v) pre-transplantation or pre-chemotherapy screening [20] .

In this study, we have clearly identified robust SARS-CoV-2 serological tests for the diagnosis of patients presenting a moderate to severe CoviD-19 diseases during acute and early subacute phase with a limited usefulness of IgM for the serologic diagnostic of SARS-CoV-2.

Our conclusion can thus only be applied to this type of patients.

Additional evaluation studies of these SARS-CoV-2 anti-N and anti-S serological tests need to be performed to assess the performance of these tests on sera collected from nonhospitalized pauci-symptomatic patients, from SARS-CoV-2 RT-PCR positive patients but more than two month post exposure, or from symptomatic SARS-CoV-2 negative RT-PCR patients non tested here for ethical reasons.

Finally, complementarity of both kind of tests (anti-N and anti-S) has clearly to be envisaged and evaluated to fulfill the best performances as they might be complementary and might permit to reach the best sensitivity and specificity for both clinical and large seroprevalence population studies. The sensitivity is given for the sample above 15 days post symptoms. The sensitivity is given for the sample above 15 days post symptoms. 

Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses. Microbes Infect

The hallmarks of COVID-19 disease

Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study

Serological assays for emerging coronaviruses: challenges and pitfalls

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes

Antibody responses to individual proteins of SARS coronavirus and their neutralization activities. Microbes Infect

The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Identification of SARS-CoV RBD-targeting monoclonal antibodies with crossreactive or neutralizing activity against SARS-CoV-2

Serological Assays for SARS-CoV-2 Infectious Disease: Benefits, Limitations and Perspectives

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. The Lancet Infectious Diseases

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Diagnostic strategies for SARS-CoV-2 infection and interpretation of microbiological results. CMI, 2020

Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients

Serological differentiation between COVID-19 and SARS infections

A serological assay to detect SARS-CoV-2 seroconversion in humans

Changes in SARS-CoV-2 Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. medRxiv

Indication for SARS-CoV-2 serology: first month follow-up. medRxiv

We warmly thank all the members of the laboratory of serology of the CHUV, Sarah 

ATC and AC wrote the first draft. All authors critically reviewed the manuscript.

This study was evaluated by our Ethics Committee (CER-VD) and they judged that it did not deserve a specific approval being only a quality assessment of diagnostic tests.

The authors have no conflicts of interest to declare.

No external funding was necessary to write this study.